Echinocandin pharmacodynamics: review and clinical implications. - Wikidata - wikimedia - TriplyDB

Echinocandin pharmacodynamics: review and clinical implications.

Echinocandin pharmacodynamics: review and clinical implications.

http://www.wikidata.org/entity/Q37718385

about

Treatment with echinocandins during continuous renal replacement therapy Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures Utility of PCR in diagnosis of invasive fungal infections: real-life data from a multicenter study.Micafungin use in children.Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies.Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.Novel method for evaluating in vitro activity of anidulafungin in combination with amphotericin B or azoles.Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.Echinocandins: The Expanding Antifungal Armamentarium.Antifungal resistance and new strategies to control fungal infections.Micafungin versus caspofungin in the treatment of Candida glabrata infection: a case report.Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.We can do better: a fresh look at echinocandin dosing.Vitamin Biosynthesis as an Antifungal Target.Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins Yeast species-specific, differential inhibition of β-1,3-glucan synthesis by poacic acid and caspofungin

P2860

Q27012864-6E941997-777A-41A1-861E-C3FF1D8D242F Q28477349-05A55A66-AE19-42C1-B343-CAE02D0B4719 Q30583368-ECF1231A-E69F-4FB4-8F1B-E95FD04FEF9B Q33397111-9A019E27-0A82-464F-8F77-8B755D4E2232 Q35666505-946B653D-DDE8-4189-8769-1B5FEEE436E0 Q35959484-9C91ECF7-7D17-4F3C-B407-580B9680669E Q35959489-A8BC17EB-2492-4B77-8705-194224073041 Q36285521-6FE0CD7F-F0EB-48E5-926C-483109E2EC70 Q36924037-C60C97D7-A44B-4401-888D-FE3A561A4706 Q37918556-1E3A2136-5CA8-4927-A3F5-EDFD67EB8C60 Q38193337-15147B83-5721-4BB3-9850-DA58D858E213 Q38363105-4AA659A9-D89D-438D-9488-F30E39FD0D28 Q38382954-D980CDC5-E472-4A88-8E88-18E31E5466A7 Q38548881-4A82BB25-6ADE-4051-921A-B96CBA13F850 Q38605120-8BFDBDE8-CF45-4A5D-8A4D-01E7D47886D3 Q38633102-29789FBC-E6AD-4B54-8219-A95D2205EEAE Q39751373-FF5D2EF6-2448-4D7D-8F8B-1E31A3CA7222 Q40080954-74909109-0DEF-4ADE-9F3B-4272C1865C01 Q40546653-9C2D5751-1BB5-4129-A35A-CC531CB76035 Q50118613-1EB93544-673C-4D2D-942D-93F17BC66931 Q55456503-5E4D5B07-092C-4066-810C-06E54496BD0F Q57746174-3D4BA898-CDA1-471F-9CF3-1637BD6C1D85 Q58128036-99CA104C-3A11-4256-A017-CFEC39A93237

P2860

Echinocandin pharmacodynamics: review and clinical implications.

http://www.wikidata.org/entity/Q37718385

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 March 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Echinocandin pharmacodynamics: review and clinical implications.

@en

Echinocandin pharmacodynamics: review and clinical implications.

@nl

type

label

Echinocandin pharmacodynamics: review and clinical implications.

@en

Echinocandin pharmacodynamics: review and clinical implications.

@nl

prefLabel

Echinocandin pharmacodynamics: review and clinical implications.

@en

Echinocandin pharmacodynamics: review and clinical implications.

@nl

P1433

Q37718385-2B730CBF-7EDE-4289-8DBB-5D833A345CC8

P1476

Q37718385-9755FA07-8393-4EFF-BC92-C0AE45D92F28

P2093

Q37718385-143D917D-F72E-492A-AD92-2A04957EEC48

Q37718385-56DDA266-B702-4445-A397-86F3997FD3FE

P2860

Q37718385-00CC6955-6A3E-47B9-83F8-85775AA2F025

Q37718385-04625288-4F47-4038-8CEC-E36926B19244

Q37718385-0F097F80-AF26-4890-AA47-5BB71A742776

Q37718385-10D6B60D-9E31-4BCE-8B4F-68907C6203B9

Q37718385-18D96122-85C0-4366-BDAD-F5E3D36F76FD

Q37718385-1BD9232A-FA00-42D7-B62F-91128B5786F2

Q37718385-1D517DD2-1BB5-46F8-B945-1E3DA9BCBDB4

Q37718385-1D910FEF-D0EF-434D-AB2E-1C0641CBA991

Q37718385-1E6B660C-65B1-4E56-88E0-A6D8D9458A56

Q37718385-1F8D1889-A6A8-431F-85EE-3D3CFE8B082E

P304

Q37718385-63B3C284-6CC1-4000-9BAF-4668E2E7CA58

P31

Q37718385-26367656-68C2-4664-A202-74A84A89AEE5

P356

Q37718385-997489FC-2335-40BC-AE3A-96D80C6F4D77

P407

Q37718385-8352E135-4196-4648-9E97-682F6F23D057

P433

Q37718385-8D81F189-E65E-4B23-A219-DD3D4EE361B0

P478

Q37718385-91C610E8-BBFA-45CE-8EF9-A4CC567F61CB

P50

Q37718385-984C5C51-9891-47BD-85D7-A7BBF87978A3

P577

Q37718385-56DFFB0E-865F-470F-AEE7-5BF0A8DF01BF

P5875

Q37718385-EDFA122E-D8CC-4C6D-B1ED-9222CD7CC163

P698

Q37718385-44DB0748-42DC-465A-8C3F-8B01B7A48472

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Echinocandin pharmacodynamics: review and clinical implications

@en

P2093

Melanie W Pound

http://www.w3.org/2001/XMLSchema#string

Richard H Drew

http://www.w3.org/2001/XMLSchema#string

P2860

A drug-sensitive genetic network masks fungi from the immune system

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin

Echinocandins in the management of invasive fungal infections, part 1

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

Echinocandins in the management of invasive fungal infections, Part 2

Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis

In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods

Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins.

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.

P304

1108-1118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKQ081

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Mary L. Townsend

P577

2010-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42541384

http://www.w3.org/2001/XMLSchema#string

P698

20335190

http://www.w3.org/2001/XMLSchema#string